Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA (NYXH) is a medical technology company that develops and commercializes neuromodulation-based therapies for obstructive sleep apnea (OSA), centered on its Genio hypoglossal neurostimulation system. The Nyxoah news feed on Stock Titan brings together company-issued announcements, regulatory disclosures and market updates that reflect how the business is progressing in its target markets.
Investors following Nyxoah’s news can track updates on U.S. and European commercialization of the Genio system, including surgeon training, account activations and the completion of commercial implants. Company press releases describe milestones such as the commercial launch of Genio in new countries, early U.S. implant activity after FDA approval, and developments in reimbursement coverage with public and private payers.
Nyxoah also regularly reports on its financial position and capital markets activity. News items include quarterly financial and operating results, preliminary revenue updates, private placements, registered direct offerings and convertible bond financings, as well as information on voting rights, share capital and transparency notifications regarding significant shareholdings. These disclosures provide context on how the company funds its commercialization and research plans.
In addition, the news stream features regulatory and legal developments, such as FDA approval of the Genio system for a defined subset of adult OSA patients, CE mark expansions, and intellectual property litigation updates referenced in company filings. By reviewing the NYXH news page, readers can see how Nyxoah communicates progress on clinical, regulatory, commercial and financing fronts over time.
Nyxoah, a medical technology company specializing in Obstructive Sleep Apnea (OSA) solutions, announced a reduction in the maximum shares available under its at-the-market equity offering program. The original cap of 6,000,000 ordinary shares has been decreased by 1,569,139 shares, bringing the new total to 4,430,861 shares. Consequently, 3,662,699 shares remain available for issuance. This adjustment increases the authorized capital by EUR 269,579. The announcement does not constitute a sale offer or solicitation. For more details, refer to section 1.5.2 of the May 22, 2024 board report on Nyxoah's investor page.
Nyxoah, a medical technology company specializing in treatments for Obstructive Sleep Apnea (OSA), announced a proposed public offering of ordinary shares in the U.S. on May 22, 2024. This offering may also include private sales to institutional investors outside the U.S. All shares are offered by Nyxoah, with no selling stockholders involved. The underwriters may purchase up to an additional 15% of shares. Proceeds will support U.S. commercialization, clinical data collection, R&D for the Genio system, and general corporate purposes. The offering is subject to market conditions and may not be guaranteed. Cantor Fitzgerald & Co. and Degroof Petercam are managing the offering.
Nyxoah reported financial and operating results for Q1 2024 on May 14, 2024. Key highlights include the DREAM U.S. pivotal study achieving co-primary endpoints, with a median AHI reduction of 70.8% and a 12-month AHI responder rate of 63.5%. The company recorded €1.2 million in sales, a 170% increase from Q1 2023. However, the operating loss increased to €12.2 million from €11.4 million last year mainly due to higher R&D expenses. The cash position was €44.3 million, down from €57.7 million at the end of 2023. CEO Olivier Taelman emphasized the positive study results and the company's readiness for a U.S. launch by the end of 2024.
Nyxoah (Euronext Brussels/Nasdaq: NYXH), a medical technology company, will release its Q1 2024 financial results on May 14, 2024, after the market closes. The announcement will be followed by a conference call at 10:30pm CET / 4:30pm ET to discuss the results.
The webcast of the call can be accessed via the Nyxoah Investor Relations page. Pre-registration is required for those wishing to ask questions during the call, with an email providing dial-in details and a unique access code for the live call to follow. The webcast will be available for replay shortly after the event concludes.
The press release announces the invitation to attend the annual and extraordinary shareholders' meetings of NYXOAH SA, a company listed on Euronext Brussels under the symbol NYXH, to be held on June 12, 2024. The meetings will address various agenda items including approval of financial statements, discharge of directors and auditors, approval of remuneration report, and appointment of directors. Shareholders can participate in person or via video conference by following specified registration and voting procedures. The press release provides detailed information on formalities, participation requirements, voting procedures, and data processing related to the meetings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.